Overview

Lacrimal Duct Stent Tube Market is predicted to value over USD xx billion by 2027 end with a CAGR of over xx% during the forecast period 2020 to 2027.

Rising patient population, growing demand for minimally invasive treatments are some of the factors responsible for the growth of the market. Dacryostenosis or nasolacrimal duct obstruction is the most prevalent lacrimal system disorder. As per the article ‘Nasolacrimal Duct Obstruction’ published in 2020, over 15% of infant patients possessing with some symptoms. The rate of spontaneous NLDO resolution with over 65% of affected children getting symptom-free within 3 months and over 85% recovering within a year. On the other hand, new-born babies at a high risk for this condition which include ectrodactyly-ectodermal dysplasia-cleft lip syndrome, trisomy 21, coloboma, heart anomaly, choanal atresia and retardation syndrome, branchiooculofacial syndrome, Goldenhar syndrome. Therefore, the rising incidence of such conditions shall propel the lacrimal duct stent tube market growth.
Lacrimal intubation has been a very prevalent surgery for congenital NLDO over the past few years. This procedure does not respond to failed probing or conservative medical treatments. Furthermore, there are other health conditions related to lacrimal duct obstruction like for instance, dacryocystitis is an inflammation caused in the nasolacrimal sac is generally followed by nasolacrimal duct blockage. Owing to the high incidence of such conditions shall boost the proliferation of the market.

Lacrimal Duct Stent Tube Market

Market Segmentation:

By Product Type
•   Monocanalicular Lacrimal Duct Stent Tube
•   Bicanalicular Lacrimal Duct Stent Tube
By End User
•   Hospitals
•   Ophthalmic Clinics
•   Others
By Region
•   North America
•   Europe
•   Asia-Pacific
•   Latin America
•   Middle East and Africa

The market is diversified into product type, end user and region. The product type segment is classified into monocanalicular lacrimal duct stent tube, bicanalicular lacrimal duct stent tube. The bicanalicular lacrimal duct stent tube is predicted to account the largest lacrimal duct stent tube market share owing to tits high rate of success, especially with child patients. Bicanalicular lacrimal tubes consists of two probes with a stent that intervenes. One probe passes through the lower punctum while the other through upper punctum. The silicone tube free ends are tied in the nose and the probes are removed.
The end user segment is categorised into hospitals, ophthalmic clinics and others. The hospitals segment is anticipated to dominate the market during the forecast period owing to advancements in hospital infrastructure and rise in the number of hospitals in the developing nations.

Regional Analysis:

The North America region is predicted to lead the market owing to improved surgical service regulations and rising awareness amongst the general population regarding the approach for these procedures. Furthermore, key market players have strategized acquisitions with major hospitals and clinics for expanding their business operations in the region.

Competitive Landscape:

The major market players associated are Aurolab, Bess Medizintechnik GmbH, FCI Ophthalmics, Gunther Weiss Scientific Glass, Kaneka Pharma America LLC.

FutureWise Key Takeaways:

• Growth prospects
• SWOT analysis
• Key market trends
• Key data-points affecting market growth

Objectives of the Study:

• To provide with an exhaustive analysis on the global lacrimal duct stent tube market by product type, by end user and by region
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
• To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:

•   We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
•   The customization Mobility Care offered are free of charge with purchase of any license of the report
•   You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com